DDC and Parkinson disease: In clinical settings, in a phase I clinical trial, the human aromatic-l-amino acid decarboxylase (hAAD) expressed from an AAV vector showed good tolerance, only minor adverse events, and a significant improvement in the Parkinson’s Disease Rating Scale (UPDRS), which was sustained for at least 2 years in patients with moderate to advanced Parkinson’s disease [218].